iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Virtu Financial LLC

Virtu Financial LLC lifted its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 84.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,493 shares of the company’s stock after purchasing an additional 8,460 shares during the period. Virtu Financial LLC owned about 0.05% of iTeos Therapeutics worth $142,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Point72 DIFC Ltd purchased a new stake in iTeos Therapeutics during the 3rd quarter worth approximately $31,000. Clear Harbor Asset Management LLC bought a new stake in shares of iTeos Therapeutics in the fourth quarter worth $96,000. SG Americas Securities LLC raised its holdings in iTeos Therapeutics by 12.2% in the fourth quarter. SG Americas Securities LLC now owns 13,866 shares of the company’s stock valued at $106,000 after acquiring an additional 1,508 shares in the last quarter. Marquette Asset Management LLC bought a new position in iTeos Therapeutics during the 4th quarter valued at $122,000. Finally, US Bancorp DE grew its holdings in iTeos Therapeutics by 40.1% during the 4th quarter. US Bancorp DE now owns 16,919 shares of the company’s stock worth $130,000 after acquiring an additional 4,843 shares in the last quarter. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ITOS has been the topic of a number of recent analyst reports. Wedbush restated an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a research note on Wednesday, March 5th. HC Wainwright reaffirmed a “buy” rating and set a $46.00 target price on shares of iTeos Therapeutics in a report on Thursday, March 6th. JPMorgan Chase & Co. lowered their price target on iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, March 6th. Finally, Wells Fargo & Company reduced their price objective on iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, March 6th.

iTeos Therapeutics Price Performance

Shares of ITOS opened at $6.32 on Monday. The company has a market cap of $241.39 million, a P/E ratio of -2.01 and a beta of 1.38. iTeos Therapeutics, Inc. has a 12 month low of $6.30 and a 12 month high of $18.75. The stock has a fifty day moving average price of $7.27 and a 200 day moving average price of $8.34.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.13. As a group, research analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.